Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

David R GandaraMartin ReckDenis Moro-SibilotJulien MazieresShirish GadgeelStefanie MorrisAndres CardonaDiana MendusMarcus BallingerAchim RittmeyerSolange Peters

Published in: Journal for immunotherapy of cancer (2021)

NCT02008227.

Keyphrases

phase iii
open label
double blind
clinical trial
placebo controlled
phase ii
radiation therapy